MedTech Dive: Labcorp Receives FDA Authorization for Groundbreaking Pan-Solid Tumor Liquid Biopsy

MedTech Dive reports that Labcorp has received FDA De Novo authorization for its PGDx elio plasma focus Dx—a kitted, pan–solid tumor liquid biopsy that profiles 33 genes related to cancer. Shakti Ramkissoon, Labcorp’s Labcorp’s vice president and medical lead for oncology, emphasized how this new test expands precision oncology options and supports more personalized, timely treatment decisions for patients facing solid tumors. Read the full article on MedTech Dive to learn how this milestone expands access to targeted cancer diagnostics.